December 7, 2006 -- Vanda Pharma, a 2006 IPO, said Iloperidone, a potential schizophrenia drug, produced positive top-line results in a Phase III trial; the good news also had a very salubrious effect on Titan Pharma, which stands to gain royalties from the compound; Genentech will collaborate with AC Immune to develop drugs for Alzheimer’s disease; Roche partnered up with Xenon to discover drugs that treat anemia of inflammation; Orthovita paid $9 million to Angiotech to buy out its royalty agreement; Cephalon said the FDA is still investigating a case of serious rash from the Sparlon clinical trial; Medarex received Fast Track designation for a cancer drug; Pharmion began a Phase II trial of a drug for MDS or leukemia; Lipid Sciences is enrolling patients in an HDL Selective Delipidation therapy; Lilly asked for approval of Evista to reduce the risk of breast cancer; and Tercica won a patent suit against Insmed. The Centient Biotech 200™ fell 26 points to 3972, a loss of .65%. More details...
